Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE vs ACTIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sodium picosulfate is a stimulant laxative that is hydrolyzed by colonic bacteria to the active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane, which stimulates colonic peristalsis by acting on the colonic mucosa and inhibiting water and electrolyte absorption. Magnesium oxide acts as an osmotic laxative by drawing water into the intestinal lumen. Citric acid reacts with magnesium oxide to form magnesium citrate, an osmotic laxative.
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Bowel cleansing prior to colonoscopy,FDA-approved for bowel preparation in adults
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
Adult: 10 mg oral sodium picosulfate (as 10 mg powder for oral solution) plus 3.5 g magnesium oxide and 12 g citric acid, taken as a single dose the day before colonoscopy, followed by a second dose the next morning, for a total of 2 doses.
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
The terminal elimination half-life of the active metabolite BHPM is approximately 7-9 hours; clinical effect (bowel cleansing) begins within 1-3 hours and is complete by 6 hours.
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Sodium picosulfate is hydrolyzed by colonic bacteria to its active metabolite. Magnesium and citrate are not metabolized; they are absorbed and excreted renally.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Sodium picosulfate is primarily excreted in feces (90-95%) as the active metabolite BHPM via biliary elimination; <5% excreted renally. Magnesium oxide is excreted renally as magnesium ions. Citric acid is metabolized to bicarbonate and excreted renally.
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
Sodium picosulfate and its active metabolite BHPM are minimally protein bound (<5%); magnesium oxide and citric acid are not significantly protein bound.
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
The volume of distribution of the active metabolite BHPM is not well defined; magnesium distributes mainly to extracellular fluid (0.2-0.4 L/kg).
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Sodium picosulfate is a prodrug; systemic bioavailability of BHPM after oral administration is approximately 10-15% due to extensive presystemic metabolism.
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
Contraindicated in patients with severe renal impairment (e GFR < 30 m L/min/1.73 m²). For e GFR 30-60, use with caution and ensure adequate hydration.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
No specific adjustment provided; use with caution in severe hepatic impairment (Child-Pugh C) due to potential for electrolyte disturbances.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
Safety and efficacy not established in pediatric patients; not recommended for use in children.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
No specific dose adjustment; ensure adequate hydration and monitor electrolyte levels due to increased risk of renal impairment and dehydration.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
Risk of acute phosphate nephropathy and renal failure, particularly in patients at increased risk (e.g., renal impairment, dehydration, medications affecting renal function).
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Do not use in patients with gastrointestinal obstruction, perforation, or ileus.,Use caution in patients with renal impairment, electrolyte abnormalities, or those taking medications that affect electrolyte balance.,Monitor for fluid and electrolyte disturbances.,Avoid use in patients with known hypersensitivity to any component.
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Gastrointestinal obstruction, ileus, or perforation,Renal failure (creatinine clearance < 30 m L/min),Ascites,Congestive heart failure (NYHA class III or IV),Known hypersensitivity to any component
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
Avoid solid food during bowel preparation. Consume only clear liquids (water, clear broth, apple juice, clear gelatin, black coffee or tea without milk, sports drinks). Avoid red, purple, or orange liquids that can be mistaken for blood during colonoscopy. Do not consume alcohol or dairy products.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
No adequate studies in pregnant women. In animal studies, sodium picosulfate showed no teratogenic effects at clinically relevant doses. Theoretical risk of electrolyte disturbances from magnesium absorption may affect fetal development; avoid in first trimester if possible. Insufficient data for second and third trimesters; use only if clearly needed.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Unknown if components excreted in human milk. Sodium picosulfate may be excreted in small amounts; magnesium and citrate are normal milk constituents. Risk to infant considered low with single doses, but caution advised with chronic use. M/P ratio not available.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
No pharmacokinetic studies in pregnancy suggest dose adjustment. Use lowest effective dose and shortest duration. Avoid chronic use due to risk of electrolyte imbalances. Single-dose bowel preparation typical; no adjustment recommended.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
Ensure adequate hydration to prevent electrolyte disturbances. Monitor renal function and serum electrolytes, especially in elderly or patients with renal impairment. Administer as a split-dose regimen for optimal bowel cleansing. Avoid use in patients with gastrointestinal obstruction, perforation, or severe inflammatory bowel disease.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
Take this medication exactly as prescribed to prepare your colon for a procedure.,Drink plenty of clear liquids before, during, and after taking this medication to prevent dehydration.,You may experience bloating, cramping, or nausea; these are common and usually resolve after the bowel movement begins.,Do not take any other laxatives or stool softeners while using this product unless directed by your doctor.,Stop taking and contact your doctor if you experience severe abdominal pain, vomiting, or signs of an allergic reaction (rash, itching, swelling).,This medication will cause frequent, watery bowel movements; stay near a bathroom.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
"Amphetamine increases renal tubular pH, which reduces the excretion rate of magnesium oxide, potentially leading to elevated serum magnesium levels. This interaction may result in hypermagnesemia, manifesting as hypotension, respiratory depression, or cardiac arrhythmias, particularly in patients with renal impairment."
"Mesoridazine, a phenothiazine antipsychotic, can chelate with magnesium ions in the gastrointestinal tract, forming insoluble complexes that reduce the absorption of magnesium oxide. This leads to diminished serum magnesium concentrations, potentially compromising magnesium's therapeutic effects for conditions such as hypomagnesemia or constipation. Clinically, patients may experience inadequate magnesium supplementation, risking exacerbation of electrolyte imbalances or reduced efficacy of magnesium-based therapies."
"Coadministration of magnesium oxide with rosuvastatin may decrease the serum concentration of rosuvastatin, potentially reducing its cholesterol-lowering efficacy. This interaction is thought to be due to chelation of the statin by magnesium ions in the gastrointestinal tract, impairing absorption. Clinically, this may lead to suboptimal lipid control and increased cardiovascular risk."
No interactions on record
Common clinical questions about CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE vs ACTIQ, answered by our medical review team.
CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE is a Laxative (Osmotic/Stimulant Combination) that works by Sodium picosulfate is a stimulant laxative that is hydrolyzed by colonic bacteria to the active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane, which stimulates colonic peristalsis by acting on the colonic mucosa and inhibiting water and electrolyte absorption. Magnesium oxide acts as an osmotic laxative by drawing water into the intestinal lumen. Citric acid reacts with magnesium oxide to form magnesium citrate, an osmotic laxative.. ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE and ACTIQ depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE is: Adult: 10 mg oral sodium picosulfate (as 10 mg powder for oral solution) plus 3.5 g magnesium oxide and 12 g citric acid, taken as a single dose the day before colonoscopy, followed by a second dose the next morning, for a total of 2 doses.. The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE and ACTIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE is classified as Category C. No adequate studies in pregnant women. In animal studies, sodium picosulfate showed no teratogenic effects at clinically relevant doses. Theoretical risk of electrolyte disturbance. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.